BankChampaign National Association Invests $614,000 in Vertex Pharmaceuticals Incorporated $VRTX

BankChampaign National Association bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,374 shares of the pharmaceutical company’s stock, valued at approximately $614,000.

A number of other institutional investors and hedge funds have also made changes to their positions in VRTX. Motiv8 Investments LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $28,000. Eagle Bay Advisors LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth $29,000. IMG Wealth Management Inc. grew its holdings in Vertex Pharmaceuticals by 277.8% during the fourth quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after acquiring an additional 50 shares during the period. Finally, Ares Financial Consulting LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth $33,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex’s planned $10 billion acquisition of Crinetics Pharmaceuticals would add endocrine assets and broaden its growth pipeline beyond cystic fibrosis. The deal also highlights Vertex’s willingness to use its strong cash-generation profile to pursue new growth opportunities. Vertex Just Paid $10 Billion for Crinetics
• Positive Sentiment: Vertex and AbCellera announced a collaboration to discover, develop, manufacture and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions. Vertex will fund the research and retain commercialization rights, potentially expanding its long-term pipeline into new therapeutic areas. AbCellera, Vertex partner on next-gen T-cell engagers
• Positive Sentiment: Erste Group Bank raised its Vertex EPS forecast to $16.95 for fiscal 2026 and $19.26 for fiscal 2027. The 2027 estimate is above the broader consensus of $17.01 for the current year, indicating improving analyst expectations.
• Neutral Sentiment: Brokerages maintain a consensus “Moderate Buy” rating. However, valuation opinions remain divided: discounted-cash-flow analysis suggests upside, while market-based multiples appear closer to fair value after the shares’ strong longer-term performance. Vertex Receives Moderate Buy Recommendation
• Neutral Sentiment: Investors are also focused on Vertex’s second-quarter 2026 results. Pre-earnings coverage is emphasizing operating metrics and pipeline progress, but no new quarterly results were reported in these articles, leaving near-term direction dependent on the upcoming release.
• Negative Sentiment: The Crinetics acquisition represents a substantial financial commitment and could pressure Vertex’s valuation if integration is difficult, development costs rise or the acquired pipeline fails to produce meaningful revenue. This appears to be the principal source of caution behind the recent weakness.

Analysts Set New Price Targets

VRTX has been the subject of a number of recent analyst reports. Sanford C. Bernstein reduced their target price on Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, July 17th. Truist Financial increased their price target on shares of Vertex Pharmaceuticals from $542.00 to $560.00 and gave the company a “buy” rating in a report on Monday, July 13th. Royal Bank Of Canada raised their price objective on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Finally, Canaccord Genuity Group reduced their price objective on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a research note on Tuesday, May 5th. Twenty-two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $559.61.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 318 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $423.73, for a total transaction of $134,746.14. Following the completion of the transaction, the director directly owned 4,924 shares in the company, valued at approximately $2,086,446.52. This trade represents a 6.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan Mckechnie sold 1,541 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total transaction of $799,779.00. Following the transaction, the executive vice president owned 11,001 shares of the company’s stock, valued at $5,709,519. This trade represents a 12.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 17,770 shares of company stock worth $8,238,744. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $481.70 on Friday. The business has a 50 day moving average price of $469.76 and a 200 day moving average price of $460.21. The company has a market capitalization of $122.26 billion, a P/E ratio of 28.57, a PEG ratio of 2.18 and a beta of 0.29. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $533.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. The company had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.Vertex Pharmaceuticals’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the previous year, the business earned $4.06 earnings per share. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 17.01 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.